RIO DE JANEIRO, BRAZIL - According to the company, there was a "statistically significant" reduction in severe cases and deaths in non-hospitalized patients who took the drug compared to those given a placebo.
In its global release on the results, the drugmaker detailed that a total of 90% of trial subjects enrolled were from high risk populations of progressing to a severe form of Covid-19, including those with comorbidities such as cancer, diabetes, obesity, and lung disease, among others.
"The trial met the primary outcome, with a 600 milligram (mg) dose of AZD7442 administered by intramuscular (IM) injection reducing . . .